Identifying the possibility of contamination outside the manufacturing process
Protecting industrial predictability and the supply chain

"The key issue was to distinguish this case from the precedent in the 'Valsartan' case, which could be seen as a similar matter."


Park Hyunsoo, attorney at Gwangjang Law Firm (33rd class of the Judicial Research and Training Institute), said this after winning a lawsuit seeking the return of unjust enrichment related to pharmaceutical impurities that the pharmaceutical industry recently filed against the health authorities. Unlike the precedent in a similar case, in which the Seoul Central District Court had recognized the liability of pharmaceutical companies, the court accepted Gwangjang's arguments and upheld the claims of the pharmaceutical companies.

Jung Daju, Park Hyunsoo and Kim Ilkwon (from left in the photo), attorneys from law firm Gwangjang, are being interviewed by The Asia Business Daily at the Gwangjang office on Namdaemun-ro in Jung-gu, Seoul. Photo by Cho Yongjun

Jung Daju, Park Hyunsoo and Kim Ilkwon (from left in the photo), attorneys from law firm Gwangjang, are being interviewed by The Asia Business Daily at the Gwangjang office on Namdaemun-ro in Jung-gu, Seoul. Photo by Cho Yongjun

View original image

The case began when, after a public notice on test methods for detecting the impurity N-nitrosodimethylamine (NDMA), NDMA was found in three active pharmaceutical ingredients, including metformin. The health authorities required pharmaceutical companies to bear the costs of re-prescription and re-dispensing. In response, the companies filed a lawsuit in July 2022 against the National Health Insurance Service for the return of unjust enrichment, arguing that the cost burden was unfair even though they had complied with the standards in force at the time of manufacturing. However, the outlook was bleak, because in a previous lawsuit over Valsartan-containing medicines, which was similar to this case, the court had ruled in favor of the health authorities.


◆Emphasizing that NDMA was not present in the active pharmaceutical ingredient

Kim Ilkwon, attorney on Gwangjang's healthcare team and a life sciences major (6th bar exam), focused on metformin, which accounted for 78% of the medicines in which impurities were detected. Attorney Kim stressed, "In the case of Valsartan, the impurity in the active pharmaceutical ingredient itself exceeded the standard by more than 100 times, whereas in metformin, no impurity was detected at all in the active ingredient."


He also pointed out that NDMA was detected only in some of the finished products. According to Gwangjang, among the finished metformin products tested by the Ministry of Food and Drug Safety, only 10.7% showed trace amounts of the impurity. This led the team to identify the possibility that the issue arose not from the manufacturing process, but from factors outside the manufacturer's sphere of control, such as distribution and storage.


◆Highlighting the different degrees of exceeding the interim control limit

It was also significant that NDMA was not detected in the active pharmaceutical ingredient in the case of metformin. For Valsartan, the NDMA detected in the active pharmaceutical ingredient had exceeded the interim control limit by more than 100 ppm. Even the NDMA detected in some finished metformin products did not exceed the interim control limit by more than 1 ppm.


According to the guidelines of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), the risk level was also low. The additional carcinogenic risk from metformin was only 0.21 cases per 100,000 people, which the team demonstrated falls into the "negligible level" at which risk is not recognized under international standards. By contrast, the additional risk from Valsartan reached 8.5 cases per 100,000 people, and was recognized as hazardous even under international criteria.


In this process, attorney Jung Daju (31st class of the Judicial Research and Training Institute) devoted considerable effort to translating scientific facts into "the language of the court." Jung said, "We used analogies such as processed meat and coffee, which can be harmful if there is excessive exposure but whose sale is not considered illegal," adding, "Eighty percent of what the litigation team did was the translation of scientific facts to help the court understand them."


◆Enhancing predictability in the pharmaceutical industry

This victory is seen as setting a precedent that, if a newly recognized issue arising from technological advances is not serious in degree, it is not reasonable to hold the product supplier liable.



Attorney Park said, "The government can set conservative standards for safety, but if it invariably shifts the resulting costs onto the private sector, what company would develop new drugs?" He added, "This victory is meaningful in that it enhances predictability in the pharmaceutical industry and has helped safeguard a stable pharmaceutical supply chain."

[Designing Victory] Focusing on Scientific Proof... Gwangjang Overturns Precedent Against Pharma Industry View original image


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing